Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Swiftscale Biologics

Explore full profile

Developed and manufactured biologic drugs

San Francisco, United StatesFounded 2019Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2020
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Swiftscale Biologics and the history behind them.

About Swiftscale Biologics

SwiftScale Bio is a pioneering biotech startup that specializes in cell-free systems for the production and purification of custom proteins. Unlike traditional methods that rely on the growth and viability of cells, SwiftScale's automated process eliminates these dependencies, significantly reducing both the time and costs involved. This innovative approach allows for rapid production of antibodies and other biologics, making it highly valuable for pharmaceutical companies and research institutions.

Read full description

The company operates in the biotechnology and pharmaceutical markets, serving clients who require fast and reliable protein production for drug development, biophysical characterization, and animal studies. SwiftScale's cell-free platform is particularly beneficial for accelerating drug pipelines, offering services from protein screening and synthesis to large-scale antibody production.

SwiftScale's business model revolves around providing high-throughput protein production services. They generate revenue by offering these specialized services to pharmaceutical companies, biotech firms, and research institutions. By enabling rapid access to preparative amounts of protein from linear DNA in less than 24 hours, SwiftScale offers a significant advantage over traditional methods that can take weeks. This speed and efficiency make their services highly attractive to clients looking to expedite their research and development processes.

In summary, SwiftScale Bio is revolutionizing the biotech industry with its cell-free protein production platform, offering a faster, more cost-effective solution for producing custom proteins and antibodies. Their innovative approach serves a critical need in the pharmaceutical and biotech markets, making them a valuable partner for companies looking to accelerate their drug development pipelines.

Source: Dealroom company data

At a glance

Founded
2019
Headquarters
San Francisco, United States
Sector
Biotech & Life Sciences

Latest news

Press, funding announcements and product moves mentioning Swiftscale Biologics.

See all news

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Swiftscale Biologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Swiftscale Biologics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.